QUEBEC CITY, April 13 /CNW Telbec/ - AEterna Zentaris Inc.
(TSX: AEZ; Nasdaq: AEZS), a global, pure play biopharmaceutical company
focused on endocrine therapy and oncology, today announced that it will
present two abstracts outlining first in vitro data on its PI3K inhibitors as
well as in vivo data on its GHRH antagonist, JMR-132, which both may
potentially provide new therapeutic approaches for the treatment of cancer.
These abstracts will be presented at the American Association for Cancer
Research (AACR) Annual Meeting, to be held April 14-18 at the Los Angeles
Convention Center in Los Angeles, California.
Selected abstracts for poster sessions in the Exhibit Hall:
Monday, April 16, 8:00 a.m. - 12:00 p.m. (PT)
- Abstract No.2379 "New Generation of Anilino-Substituted
Pyridopyrazine-Urea Derivatives Show Highly Selective PI3K-
Inhibition". Irene Seipelt, Eckhard Claus, Tilman Schuster,
Emmanuel Polymeropoulos, Michael Teifel, Eckhard Gunther.
The abstract reviews, for the first time, results of a preclinical
development program on a new generation of pyridopyrazine
derivatives which clearly indicate that these drug candidates
selectively inhibit PI3K and could be valuable for the treatment of
Tuesday, April 17, 8:00 a.m. - 12:00 p.m. (PT)
- Abstract No.3568 "GHRH-Antagonist in Combination with Docetaxel
Chemotherapy induces regression of MX-1 human experimental breast
cancers". Joerg B. Engel, Andrew V. Schally, Jozseph Varga, Gabor
Halmos, Stefan Buchholz.
The abstract reviews results which demonstrate that GHRH
antagonist, JMR-132, inhibits doxorubicin resistant in MX-1 human
breast cancers and induces growth arrest or total regression when
combined with docetaxel chemotherapy. Consequently, JMR-132 could
provide a new therapeutic approach for the treatment of early and
metastatic breast cancer.
Copies of these abstracts are currently available and can be viewed
on-line through the AACR 2007 Meeting website at:
About AEterna Zentaris Inc.
AEterna Zentaris Inc. is a global, pure play biopharmaceutical company
focused on endocrine therapy and oncology with proven expertise in drug
discovery, development and commercialization.
News releases and additional information are available at
This press release contains forward-looking statements made pursuant to
the safe harbor provisions of the U.S. Securities Litigation Reform Act of
1995. Statements that are not historical facts, including statements preceded
by, followed by, or that include the words "believes", "anticipates",
"intends", "plans", "expects", "estimates", "will," "may", "should",
"approximately", and the negative or other variations of those terms or
comparable terminology, are forward-looking statements. Such statements
reflect management's current views, intentions, strategies and plans and are
based on certain assumptions.
Forward-looking statements involve known and unknown risks and
uncertainties, which could cause the Company's actual results to differ
materially from those in the forward-looking statements. Such risks and
uncertainties include, among others, the ability of AEterna Zentaris to
implement its business strategies, the availability of funds and resources to
pursue R&D projects, the successful and timely completion of clinical studies,
the ability of AEterna Zentaris to take advantage of business opportunities in
the pharmaceutical industry, uncertainties related to the regulatory process
and general changes in economic conditions. Investors should consult the
Company's quarterly and annual filings with the Canadian and U.S. securities
commissions for additional information on risks and uncertainties relating to
the forward-looking statements. Investors are cautioned not to rely on these
forward-looking statements. The Company does not undertake to update these
For further information:
For further information: Jenene Thomas, Senior Director, Investor
Relations & Corporate Communications, (418) 655-6420,
email@example.com; Paul Burroughs, Media Relations, (418)
652-8525 ext. 406, firstname.lastname@example.org